(Q36936936)

17 August 2017

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial (English)

1 reference

17 August 2017

1 reference

11

Bernard Escudier

1 reference

17 August 2017

3

Cezary Szczylik

1 reference

17 August 2017

Tim Eisen

1

1 reference

17 August 2017

Stéphane Oudard

2

1 reference

17 August 2017

Gwenaelle Gravis

4

1 reference

17 August 2017

Hans Heinzer

5

1 reference

17 August 2017

Richard Middleton

6

1 reference

17 August 2017

Frank Cihon

7

1 reference

17 August 2017

Sibyl Anderson

8

1 reference

17 August 2017

Sonalee Shah

9

1 reference

17 August 2017

Ronald Bukowski

10

1 reference

17 August 2017

TARGET Study Group

12

1 reference

17 August 2017

language of work or name

English

0 references

publication date

7 October 2008

1 reference

Journal of the National Cancer Institute

17 August 2017

1 reference

17 August 2017

100

1 reference

17 August 2017

20

1 reference

17 August 2017

1454-1463

1 reference

The epidemiology of bladder and kidney cancer

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Sorafenib in advanced clear-cell renal-cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Epidemiologic aspects of renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Global cancer statistics, 2002

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

A case for geriatric oncology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

The presentation, treatment and outcome of renal cell carcinoma in old age.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2567417

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

4 September 2018

1 reference

12 December 2020

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

1 reference

12 December 2020

Influence of age on the prognosis of patients with renal cell carcinoma (RCC)

1 reference

12 December 2020

Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?

1 reference

12 December 2020

Altered angiogenesis underlying age-dependent changes in tumor growth

1 reference

12 December 2020

Efficacy of anti-angiogenic treatment of tumors in old versus young mice

1 reference

12 December 2020

Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJN319

1 reference

release_siycslnv3fgdtmoot466pymw64

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/siycslnv3fgdtmoot466pymw64

24 November 2022

mapped directly with Wikidata item

1 reference

17 August 2017

PubMed publication ID

18840822

1 reference